Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study
Authors' conclusion
This study defines and characterizes refractory PAH. The distinct clinical characteristics and the proposed structured diagnostic-therapeutic pathway offer a framework for managing this challenging condition.
Study context
- Population
- Patients with primary autoimmune hypophysitis (PAH); refractory PAH defined as primary glucocorticoid (GC) resistance or recurrence during tapering (GC-dependent)
- Participants
- 100 PAH patients
- Exposure
- Refractory vs non-refractory PAH, baseline characteristics
- GC-dependent refractory hypophysitisn = 19
- GC-resistant hypophysitisn = 3
- Outcome
- Refractory disease
Main finding
As reported in the abstract
Met the criteria for refractory disease
22
22%
GC-dependent hypophysitis
19
GC-resistant hypophysitis
3
Observational data: associations, not effects.
Further findings
| Outcome | GC-dependent refractory hypophysitis | Non-refractory | P value |
|---|---|---|---|
| Pregnancy-associated hypophysitisGC-dependent refractory hypophysitis vs Non-refractory · lower prevalence with GC-dependent refractory hypophysitis | 5.9% | 41.7% | P = 0.006 |
| Serum prolactinGC-dependent refractory hypophysitis vs Non-refractory · higher with GC-dependent refractory hypophysitis · median, ng/mL | 30.2 | 17.8 | P = 0.021 |
| Hypogonadotropic hypogonadismGC-dependent refractory hypophysitis vs Non-refractory · higher prevalence with GC-dependent refractory hypophysitis | 82.4% | 55.4% | P = 0.040 |
| Pituitary stalk diameterGC-dependent refractory hypophysitis vs Non-refractory · larger with GC-dependent refractory hypophysitis · median, mm | 5.5 | 3.7 | P = 0.043 |
GC-resistant vs non-refractory
- No significant differences were observed between the GC-resistant group and the non-refractory group
Radiological control
- Combination therapy with immunosuppressive agents (e.g., mycophenolate mofetil) or rituximab was effective in achieving radiological control
Safety
- Glucocorticoid-related adverse events, most commonly hyperlipidemia and hyperglycemia
- 40.9% of patients
Original publication
Clinical Features and Management Framework for Refractory Hypophysitis: A Cohort Study. J Clin Endocrinol Metab. Published 12 November 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →